Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12267115 | 0.83 | ALDH1A1 (0.44) | ADORA3ADORA2AADORA1ADORA2BSMN1; SMN2 | |
| SCHEMBL22322457 | 0.81 | MAPT (0.62) | ADORA3ADORA2AADORA1ADORA2BSMN1; SMN2 | |
| SCHEMBL12266907 | 0.80 | MEN1 (0.49) | ADORA3ADORA2AADORA1ADORA2BSMN1; SMN2 | |
| SCHEMBL2361575 | 0.79 | ADORA3 (0.61) | ADORA3ADORA2AADORA1ADORA2BSMN1; SMN2 | |
| SCHEMBL5395670 | 0.79 | APP (0.44) | ADORA3ADORA2AADORA1ADORA2BSMN1; SMN2 | |
| SCHEMBL8595731 | 0.79 | CYP19A1 (0.40) | ADORA3ADORA2AADORA1ADORA2BSMN1; SMN2 | |
| SCHEMBL1616385 | 0.79 | CYP19A1 (0.63) | ADORA3ADORA2AADORA1ADORA2BSMN1; SMN2 | |
| SCHEMBL21105030 | 0.79 | CYP19A1 (0.42) | ADORA3ADORA2AADORA1ADORA2BL3MBTL1 | |
| SCHEMBL9147912 | 0.79 | CYP19A1 (0.67) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL14518686 | 0.79 | IDO1 (0.42) | ADORA3ADORA2AADORA1ADORA2BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107557-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11659766-B2 | Organic semiconductor material for electron transport | DAEGU GYEONGBUK INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2023-05-23 | — | — | US | disclosed |
| US-11659766-B2 | Organic semiconductor material for electron transport | DAEGU GYEONGBUK INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2023-05-23 | — | — | US | disclosed |
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AG (DE) | 2020-12-17 | — | — | US | disclosed |
| EP-3632919-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3243826-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190189933-A1 | ORGANIC SEMICONDUCTOR MATERIAL FOR ELECTRON TRANSPORT | DAEGU GYEONGBUK INSTITUTE OF SCIENCE & TECHNOLOGY (KR) | 2019-06-20 | — | — | US | disclosed |
| WO-2018114596-A1 | SUBSTITUTED HETEROARYL PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| EP-3243826-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2011020849-A1 | CYTOHESIN INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT (DE) | 2011-02-24 | — | — | WO | disclosed |
| EP-2286808-A1 | Cytohesin inhibitors | Rheinische Friedrich-Wilhelms Universität (DE) | 2011-02-23 | — | — | EP | disclosed |
| US-7371759-B2 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | DDT, NOTUM, AGPS | ADORA3 1975/4885ADORA2A 2413/4885ADORA1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.